Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 157 for:    Enzyme | curcumin

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02494141
Recruitment Status : Recruiting
First Posted : July 10, 2015
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

Condition or disease Intervention/treatment Phase
Polycystic Kidney, Autosomal Dominant Drug: Curcumin Other: Placebo Phase 4

Detailed Description:
Although often considered to be a disease of adults, complications of autosomal dominant polycystic kidney disease (ADPKD) begin in childhood. While ADPKD causes the continued growth of multiple kidney cysts that ultimately result in loss of kidney function, the leading cause of death among patients with ADPKD is cardiovascular disease. Treatment options to prevent cardiovascular disease in adults with ADPKD are limited, thus childhood may be an important time to reduce risk. Curcumin is a safe, naturally occurring substance found in the Indian spice tumeric, which is in curry powder. The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with ADPKD. The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
Actual Study Start Date : November 12, 2015
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Curcumin

Arm Intervention/treatment
Experimental: Curcumin
25/mg/kg per day for 1 year.
Drug: Curcumin
Dietary Supplement
Other Name: Longvida

Placebo Comparator: Placebo
Equivalent placebo for 1 year.
Other: Placebo



Primary Outcome Measures :
  1. Change in Brachial artery flow-mediated dilation (FMD-BA) (% change) [ Time Frame: Baseline, Month 12 ]
    co-primary endpoint

  2. Change in Aortic pulse-wave velocity (aPWV) (cm/sec) [ Time Frame: Baseline, Month 12 ]
    co-primary endpoint


Secondary Outcome Measures :
  1. Change in Urinary 8-iso-prostaglandin F2α (8-isoprostane) [ Time Frame: Baseline, Month 12 ]
    Urine marker of oxidative stress

  2. Change in 8-hydroxy 2 deoxyguanosine (8-OHdG) [ Time Frame: Baseline, Month 12 ]
    Urine marker of oxidative stress

  3. Change in C-reactive protein [ Time Frame: Baseline, Month 12 ]
    Circulating marker of inflammation

  4. Change in Interleukin-6 [ Time Frame: Month 12 ]
    Circulating marker of inflammation

  5. Change in Oxidative Stress-Associated Suppression of endothelium-dependent dilation (EDD) [ Time Frame: Baseline, Month 12 ]
    The influence of oxidative stress on FMD-BA will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline.

  6. Change in Oxidative Stress-Associated Suppression of Large Elastic Artery Stiffness [ Time Frame: Baseline, Month 12 ]
    The influence of oxidative stress on aPWV will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline.

  7. Change in Height-corrected total kidney volume [ Time Frame: Baseline, Month 12 ]
    Total kidney volume will be measured by MRI


Other Outcome Measures:
  1. Change in Plasma curcumin level [ Time Frame: Baseline, Month 12 ]
    Circulating levels of curcumin will be measured to verify delivery

  2. Change in Alanine transaminase (ALT ) [ Time Frame: month 1, 6, and 12 ]
    Liver enzymes will be monitored for safety.

  3. Change in Aspartate aminotransferase (AST) [ Time Frame: month 1, 6, and 12 ]
    Liver enzymes will be monitored for safety.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ADPKD diagnosis
  • Normal renal function (estimated glomerular filtration rate >80 mL/min/1.73m^2)
  • Ability to provide informed consent

Exclusion Criteria:

  • Currently taking a curcumin supplement
  • Current smoking or history of smoking in the past 12 months
  • Marijuana use within 2 weeks prior to FMDBA and aPWV testing
  • Antioxidantand/or omega-3 fatty acid use within the past 4 weeks prior to FMDBA and aPWV testing and for the duration of the study
  • Alcohol dependence and abuse
  • History of hospitalization within the last 3 months
  • Active infection or antibiotic therapy
  • Pregnancy, lactation, or unwillingness to use adequate birth control
  • Body-mass index >95th percentile in ages 6-17 or >40 kg/m2 in ages 18-25
  • Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02494141


Contacts
Layout table for location contacts
Contact: Kristen L Nowak, Ph.D. 3037247790 Kristen.Nowak@ucdenver.edu

Locations
Layout table for location information
United States, Colorado
University of Colorado Anschutz Medical Campus Recruiting
Aurora, Colorado, United States, 80045
Contact: Kristen L Nowak, Ph.D.    303-724-4842    Kristen.Nowak@ucdenver.edu   
Contact: Laurel Thur    303-724-9508    Laurel.Thur@ucdenver.edu   
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Kristen L Nowak, Ph.D. University of Colorado - Anschutz Medical Campus

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02494141     History of Changes
Other Study ID Numbers: 15-0902
First Posted: July 10, 2015    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Enzyme Inhibitors
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Kidney Diseases, Cystic
Kidney Diseases
Urologic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Ciliopathies
Genetic Diseases, Inborn
Curcumin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action